This statistic shows the share of drugs in clinical development and regulatory review that have the potential to be first-in-class as of 2016, by therapeutic area. Some 86 percent of Alzheimer's disease drugs in clinical development had the potential to be first-in-class, as of 2016.
Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
PhRMA. (July 24, 2018). Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/
PhRMA. "Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area." Chart. July 24, 2018. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/
PhRMA. (2018). Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area. Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/
PhRMA. "Share of Products in Clinical Development and Review That Had Potential to Be First-in-class in 2016, by Therapeutic Area." Statista, Statista Inc., 24 Jul 2018, https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/
PhRMA, Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/ (last visited November 10, 2024)
Share of products in clinical development and review that had potential to be first-in-class in 2016, by therapeutic area [Graph], PhRMA, July 24, 2018. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/886380/first-in-class-drug-development-by-therapeutic-area/
